|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-[3-[2-(2-methoxyethoxy)ethoxy]prop-1-ynyl]-3-[[2-(trifluoromethyl)phenyl]methyl]quinazolin-4-one |
Synonyms ![]() |
RV-6153 |
Comments |
RV6153 is a clinical stage PI3Kγδ inhibitor [1] that is being developed by Janssen Biotech subsidiary RespiVert. The chemical structure is claimed in patent US9227977B2 [2]. It is a derivative of RV1729. RV6153 is selective for PI3Kγδ over the α and β enzyme isoforms. |
Database Links ![]() |
|
BindingDB Ligand | 200638 |
ChEMBL Ligand | CHEMBL3934989 |
GtoPdb PubChem SID | 381118873 |
PubChem CID | 86268622 |
Search Google for chemical match using the InChIKey | JTACVHJPXOKMTI-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | JTACVHJPXOKMTI |
Search UniChem for chemical match using the InChIKey | JTACVHJPXOKMTI-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | JTACVHJPXOKMTI |